Lead identification to generate isoquinolinedione inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment

MEDI 315

Scott C. Mayer, mayers@wyeth.com1, Annette L. Banker, bankera@wyeth.com1, Frank Boschelli2, Li Di, Dil@wyeth.com3, Mark Johnson4, Cynthia Hess Kenny5, Girija Krishnamurthy, krishng@wyeth.com6, Kristina Kutterer5, Franklin Moy4, Susan Petusky1, Malini Ravi, ravim@wyeth.com5, Diane Tkach2, Hwei-Ru Tsou, Tsouh@wyeth.com5, and Weixin Xu4. (1) Chemical & Screening Sciences, Wyeth Research, Princeton, NJ, CN 8000, Princeton, NJ 08543, (2) Oncology, Wyeth Research, Pearl River, NY, 401 N. Middletown Road, Pearl River, NY 10965, (3) Chemical and Screening Sciences, Wyeth Research, Princeton, NJ, CN 8000, Princeton, NJ 08543, (4) Chemical & Screening Sciences, Wyeth Research, Cambridge, MA, Cambridge, MA, (5) Chemical & Screening Sciences, Wyeth Research, Pearl River, NY, 401 N. Middletown Road, Pearl River, NY 10965, (6) Chemical and Screening Sciences, Wyeth Research, 401 N. Middletown Rd, Pearl River, NY 10965
Insulin-like growth factor receptor (IGF-1R) is a growth factor receptor tyrosine kinase that acts as a critical mediator of cell proliferation and survival. This receptor is over-expressed or activated in tumor cells and is emerging as a novel target in cancer therapy. Efforts in our “Hit to Lead” group have generated a novel series of submicromolar IGF-1R inhibitors based on a isoquinolinedione template originating from a Lance enzyme HTS screen. Chemical triage and parallel synthesis incorporating focused library arrays were instrumental in moving these investigations through the Wyeth exploratory medicinal chemistry process. The strategies, synthesis, and SAR behind this interesting kinase scaffold will be discussed in more detail.
 

Poster Session
7:00 PM-9:00 PM, Wednesday, August 22, 2007 BCEC -- Exhibit Hall - B2, Poster

Division of Medicinal Chemistry

The 234th ACS National Meeting, Boston, MA, August 19-23, 2007